Understanding how disruptions in specific proteins lead to cancer development
Mechanisms of genomic instability, tumor initiation and progression following the disruption of the RTF2-RNase H2 axis
This study is looking at how a protein called RTF2 helps control another protein that protects our DNA, and it's specifically for people with Chronic Lymphocytic Leukemia (CLL) to better understand how their condition might affect treatment responses.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10880368 on NIH RePORTER |
What this research studies
This research investigates the role of the RTF2 protein in regulating RNase H2, an enzyme that protects our DNA from instability caused by RNA incorporation. By studying how these proteins interact, the research aims to uncover mechanisms that contribute to genomic instability, particularly in Chronic Lymphocytic Leukemia (CLL). The team has developed cellular models to explore these interactions and has created a novel assay to analyze RNA incorporation in human cells. This work could help predict how patients with CLL respond to certain treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Chronic Lymphocytic Leukemia, particularly those with genomic instability.
Not a fit: Patients without Chronic Lymphocytic Leukemia or those not exhibiting genomic instability may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients with Chronic Lymphocytic Leukemia.
How similar studies have performed: Other research has shown promising results in understanding genomic instability in cancers, making this approach both relevant and potentially impactful.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Blobel, Nicolas Johannes — Weill Medical Coll of Cornell Univ
- Study coordinator: Blobel, Nicolas Johannes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.